| ¿µ¹® | lymphatic system | ÇÑ±Û | ¸²ÇÁ°è |
|---|---|---|---|
| ¼³¸í | ´ë°³ ¸Æ°ü°è¶ó°í Çϸé, Ç÷°ü°è¿Í ¸²ÇÁ°ü°è¸¦ ÇÕÃļ ¸»ÇÑ´Ù. ÀÌÁß¿¡ ¸²ÇÁ¿¡ ÀÇÇØ ÀÌ·ç¾îÁö´Â ÇϳªÀÇ °èÅëÀÌ´Ù. |
||
| ¿µ¹® | immune system | ÇÑ±Û | ¸é¿ªÃ¼°è |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷¼ººÐ ¹× ºÐÀÚ¼ººÐÀÇ º¹ÇÕü°è·Î¼, ÀÌÀÇ ÀÏÂ÷±â´ÉÀº ÀÚ±â(self)¸¦ ºñÀÚ±â(not self)·ÎºÎÅÍ ±¸º°ÇÏ°í ¿ÜºÎ»ý¹° ¶Ç´Â ¹°Áú¿¡ ´ëÇØ ¹æ¾îÇÏ´Â °ÍÀÌ´Ù. ÀÏÂ÷ÀûÀÎ ¼¼Æ÷¼ººÐÀº ¸²ÇÁ±¸¿Í Å«Æ÷½Ä¼¼Æ÷À̸ç ÀÏÂ÷ÀûÀÎ ºÐÀÚ¼ººÐÀº Ç×ü¿Í ¸²Æ÷Ä«ÀÎÀÌ´Ù. |
||
| ¿µ¹® | urinary system | ÇÑ±Û | ºñ´¢±â°èÅë |
|---|---|---|---|
| ¼³¸í | ºñ´¢±â°èÅëÀ̶óÇϸé ÄáÆÏÀ¸·ÎºÎÅÍ ½ÃÀÛÇØ¼ ¿ä°ü, ¹æ±¤, ¿äµµ¿¡ À̸£´Â ÀÏ·ÃÀÇ ¿ÀÁÜ»ý¼º ¹× ÀúÀå, ¹è¼³±â°üÀ» ÀÏÄ´´Ù. ÄáÆÏÀº ±æÀÌ ¾à 2.5cm, Æø ¾à 5.1cm, µÎ²² ¾à 2.5cm, ¹«°Ô ¾à 120~160gmÀ¸·Î¼, ³»Ãø¿¡ ÄáÆÏ¹®ÀÌ ÀÖ¾î Ç÷°ü, ½Å°æ, ¿ä°üÀÌ ÃâÀÔÇϰí ÀÖ´Ù. ÄáÆÏÀº ¼ÓÁú°ú °ÑÁú·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç ¼öÁúÀº 10~15°³ÀÇ Ãßü(¿ÀÁÜÀ» ¸ðÀ¸´Â ¿ªÇÒ)¸¦ Çü¼ºÇÏ°í °ÑÁúÀº ¾à 100¸¸°³ÀÇ ÄáÆÏ´ÜÀ§À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ¿ä¼¼°üÀº Å丮ÂÊ´¢¼¼°ü, Çî·¹°í¸®, ¸ÕÂÊ´¢¼¼°ü, ÁýÇÕ°üÀ¸·Î Çü¼ºµÇ¾î ÀÖÀ¸¸ç, Ãßü¿Í ¼úÀÜ, ±ò¶§±â¸¦ °ÅÃÄ ¿ä°üÀ¸·Î ¿¬°áµÈ´Ù. ÄáÆÏÀº Ç÷¾×À» ¿©°úÇÏ¿© ½Åü ½ÅÁø´ë»çÀÇ ÃÖÁ¾»ê¹°À» ¿ÀÁÜÀÇ ÇüÅ·Π¹è¼³Çϸç, ¼¼Æ÷¿Ü¾×(extracellular fluid)ÀÇ ÀüÇØÁú³óµµ¸¦ Á¶ÀýÇÑ´Ù. ÄáÆÏ¿¡¼ Çü¼ºµÈ ¿ÀÁÜ´Â ¿ä°üÀ» °ÅÃÄ ¹æ±¤¿¡¼ ÀúÀåµÇ°í ÀÖ´Ù°¡ Àû´çÇÑ ½Ã±â°¡ µÇ¸é ¿äµµ¸¦ ÅëÇØ ¿Ü°è·Î ¹èÃâµÈ´Ù. |
||
| ¿µ¹® | reproductive system | ÇÑ±Û | »ý½Ä±â°èÅë |
|---|---|---|---|
| ¼³¸í | 1.³²¼º»ý½Ä°èÅë: ³²¼º»ý½Ä±â´Â Á¤ÀÚ(sperm)¸¦ »ý¼ºÇÏ´Â °íȯ°ú Á¤ÀÚÀÇ ¼º¼÷, ¿î¹Ý, ±×¸®°í »çÁ¤¿¡ °ü¿©ÇÏ´Â ºÎ°íȯ, Á¤°ü, À½°æ(penis) µîÀ¸·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç, ºÎ¼Ó±â°üÀ¸·Î ¿ÜºÐºñ»ùÀÎ Á¤³¶(seminal vesicle), Àü¸³»ù(prostate), ¿äµµ¸Á¹°»ù(bulbourethral gland, Cowper¡¯s gland) µîÀ» °®Ãß°í ÀÖ´Ù. °íȯÀº Á¤ÀÚ¸¦ »ý»êÇÏ´Â »ý½Ä»ùÀÎ µ¿½Ã¿¡ ³²¼ºÈ£¸£¸ó(testosterone)À» ºÐºñÇÏ´Â ³»ºÐºñ»ùÀÌ´Ù. °íȯ¿¡¼ ºÐºñµÇ´Â ³²¼ºÈ£¸£¸óÀº Á¤ÀÚ»ý¼º°ú »ý½Ä±âÀÇ ¹ß´Þ ¹× À¯Áö¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇϹǷΠ³²¼º»ý½Ä±â´ÉÀÇ ¿øÃµÀº °íȯ¿¡ ÀÖ´Ù°í º¼ ¼ö ÀÖ´Ù. 2.¿©¼º»ý½Ä°èÅë: ¿©¼º»ý½Ä±â´Â ³ÀÚ¸¦ »ý¼ºÇÏ´Â ³¼Ò¿Í ³ÀÚ¸¦ ÀÚ±ÃÀ¸·Î ¿î¹ÝÇÏ´Â ³°ü, ±×¸®°í Àڱðú Áú·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç ¿ÜºÐºñ¼±ÀÎ ¹Ù¸£Å縰»ù¸¦ °®Ãß°í ÀÖ´Ù. ³¼Ò´Â ³ÀÚ¸¦ »ý¼ºÇÏ´Â »ý½Ä»ùÀÎ µ¿½Ã¿¡ ¿©¼ºÈ£¸£¸óÀ» ºÐºñÄÉÇÏ´Â ³»ºÐºñ»ùÀÌ´Ù. ¿ù°æÁÖ±â Àü¹ÝºÎ¿¡ ³ÀÚ¸¦ »ý¼º½Ã۱âÀ§ÇØ ¼º¼÷µÇ°í ÀÖ´Â ³Æ÷¿¡¼ ºÐºñµÇ´Â ¿¡½ºÆ®·Î°ÕÀº ¿©¼º 2Â÷ ¼ºÂ¡ÀÇ ¹ß´ÞÀ» °üÀåÇÒ »Ó ¾Æ´Ï¶ó Àڱ󻸷À» ÀåÂ÷ ¼öÁ¤µÉ ¼öÁ¤¶õÀÌ Âø»óÇϱ⿡ ¾Ë¸ÂÀº »óÅ·Π¸¸µé¾îÁØ´Ù. ³ÀÚ°¡ ºÐºñµÇ°í ³²Àº Ȳü¿¡¼ ºÐºñµÇ´Â Ǫ·Î°Ô½ºÅ×·ÐÀº Àڱ󻸷À» º×µµ·Ï ÇÏ¸é ºÐºñ¾×À» Áõ°¡½Ã۸ç ÀڱñÙÀÇ ¼öÃàÀ» ¹æÇØÇÏ¿© ÀӽŽà ÀÓ½ÅÀ» Áö¼Ó½ÃŰ´Â ¿ªÇÒÀ» ÇÑ´Ù. |
||
| ¿µ¹® | digestive system | ÇÑ±Û | ¼Òȱâ°èÅë |
|---|---|---|---|
| ¼³¸í | ¸ÔÀº À½½ÄÀÇ ºÐÇØ, ¼ÒÈ, Èí¼ö¿¡ °ü°èµÈ Àå±â¸¦ ÅëÄªÇØ¼ ºÎ¸£´Â ¸». |
||
| EHPH | extrahepatic portal hypertension |
|---|---|
| EPI | echo planar imaging; electronic portal imaging; Emotion Profile Index; epilepsy; epinephrine; epithe... |
| EPID | electronic portal imaging device |
| FPP | faculty practice plan; free portal pressure |
| HOPP | hepatic occluded portal pressure |
| hypothalamohypophysial portal circulation | A capillary network that carries hypophyseotropic hormones from the hypothalamus, where they are secreted into blood, to their sites of action in the anterior hypophysis. See: portal circulation, hypophysis, hypothalamus. Synonym: hypophyseoportal system, hypophysial portal circulation, hypophysial portal system, hypophysioportal system, hypothalamohypophysial portal circulation, hypothalamohypophysial portal system. (05 Mar 2000) |
|---|---|
| splenic portal venography | Introduction of radiopaque material into the spleen to obtain an X-ray visualization of the portal vessel of the portal circulation. Synonym: splenic portal venography. Origin: spleno-+ portography (05 Mar 2000) |
| transverse part of left branch of portal vein | <anatomy, vein> The long unbranched portion of the left branch of the portal vein. Synonym: pars transversa rami sinistri venae portae hepatis. (05 Mar 2000) |
| umbilical part of left branch of portal vein | <anatomy, vein> The highly branched part of the left branch of the portal vein; the round and venous ligaments attach to this part. Synonym: pars umbilicalis rami sinistri venae portae hepatis. (05 Mar 2000) |
| acute renal failure | <nephrology> A sudden decline in renal function may be triggered by a number of acute disease processes. Examples include sepsis (infection), shock, trauma, kidney stones, kidney infection, drug toxicity (aspirin or lithium), poisons or toxins (drug abuse) or after injection with an iodinated contrast dye (adverse effect). Chronic renal failure represents a slow decline in kidney function over time. Chronic renal failure may be caused by a number of disorders which include long-standing hypertension, diabetes, congestive heart failure, lupus or sickle cell anaemia. Both forms of renal failure result in a life-threatening metabolic derangement. (27 Sep 1997) |
| aminoaciduria, renal | Impairment of renal tubular transport of amino acids. (12 Dec 1998) |
| back-pressure renal atrophy | <radiology> Caliectasis without obstruction, due to repeated episodes of obstruction, gradual loss of renal pyramids (12 Dec 1998) |
| base of renal pyramid | The outer broad part of a renal pyramid that lies next to the cortex. Synonym: basis pyramidis renis. (05 Mar 2000) |
| branchio-oto-renal syndrome | <syndrome> An autosomal dominant disorder manifested by various combinations of preauricular pits, branchial fistulae or cysts, lacrimal duct stenosis, hearing loss, structural defects of the outer, middle, or inner ear, and renal dysplasia. Associated defects include asthenic habitus, long narrow facies, constricted palate, deep overbite, and myopia. Hearing loss may be due to mondini type cochlear defect and stapes fixation. (12 Dec 1998) |
| capsular branches of renal artery | <anatomy, artery> Branches arising from the renal artery outside of the kidney that are distributed to the renal capsule. Synonym: rami capsulares arteriae renalis. (05 Mar 2000) |
| captopril renal scan | <radiology> In a kidney with a lesion in the afferent arteriole (e.g. Atherosclerotic plaque), reflex constriction of the efferent arteriole occurs through angiotensin system thus maintaining renal perfusion. ACE inhibition prevents constriction of efferent arteriole. Therefore, perfusion is decreased to a kidney with afferent lesions and the renal scan to looks WORSE. Bottom line: renal scans appear WORSE with captopril administration if there is a lesion in the afferent arteriole. See: renal artery stenosis (12 Dec 1998) |
| carcinoma, renal cell | Carcinoma of the renal parenchyma usually occurring in middle age or later and composed of tubular cells in varying arrangements. It was first described in 1826. Possible causal factors are environmental, hormonal, cellular, and genetic. Smoking is a definite risk factor and obesity is associated with increased risk. Renal cell carcinoma accounts for approximately 3% of adult cancer; the male-female ratio is 2:1. It is more common among urban residents than rural. (12 Dec 1998) |
| renal | <anatomy> Pertaining to the kidney, nephric. (18 Nov 1997) |
| renal adenocarcinoma | <radiology> Hypernephroma, renal cell carcinoma, arises from proximal collecting tubule, 10% bilateral adenocarcinoma types: papillary, alveolar, onchocytoma vascularity, 85% hypervascular (require pre-op embolization), 10% hypovascular (usually papillary type), 5% avascular associated with: tuberous sclerosis, von Hippel-Lindau syndrome see also: staging (12 Dec 1998) |
| renal adenocarcinoma: staging | <radiology> Typical presentation: Haematuria . . . . . 70% Fever . . . . . . . 16% Pain . . . . . . . . 50% Polycythemia . . . . 3% Palpable mass . . . 20% Anatomic staging (TNM): T1 Small tumour, kidney not enlarged T2 Large tumour, contained within renal capsule T3 Extension into perinephric fat or renal vein T4 Invasion of adjacent organs (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|